Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa (HIDRA)
Primary Purpose
Hidradenitis Suppurativa
Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Excision of HS followed by NPWTi
Excision of HS followed by NPWT
Sponsored by
About this trial
This is an interventional treatment trial for Hidradenitis Suppurativa focused on measuring Hidradenitis Suppurativa, Negative pressure wound therapy with instillation, Negative pressure wound therapy
Eligibility Criteria
Inclusion Criteria:
- Male and female
- Age 18-90 at the time of consent
- Clinical diagnosis of axillary hidradenitis suppurativa
- Unilateral axillary hidradenitis suppurativa (if bilateral disease, only one side will be included into study).
- Hidradenitis suppurativa with multiple sinuses which are not able to close directly
- Not on antibiotics for 6 weeks
- Patient understands and is willing to participate
Exclusion Criteria:
- Hidradenitis suppurativa with isolated sinus for direct closure
- Patient with ongoing chemotherapy or radiotherapy
- Patient with active cancer
- Uncontrolled Diabetes Mellitus, as measured by an HbA1c > 10%.
- BMI over 35
- Active smoker
- Presence of one or more medical conditions, including renal, hepatic, hematologic, active auto-immune or immune diseases that, would make the subject an inappropriate candidate for this wound healing study
- Patient not fit for surgery (ASA classification > 4)
- Patients not able to consent for procedure in English
Sites / Locations
- Royal Free NHS Foundation Trust Hospital LondonRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Negative Pressure Wound Therapy with instillation
Negative Pressure Wound Therapy
Arm Description
Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
Outcomes
Primary Outcome Measures
The mean days to wound coverage with split skin graft (SSG) after excision of HS
Mean days to wound coverage with split skin graft (SSG) after excision of HS in each treatment arm
The difference in bacterial count on the wound after NPWTi against NPWT
Reduction in the number of colony-forming unit (CFU) at each dressing change analysed using tissue culture of wound bed biopsies
Secondary Outcome Measures
Proportion of wounds covered with SSG at 1 week post excision
The proportion of wounds (in percentage) covered with split skin graft at 1 week post excision.
Percentage of graft take at week 1 and week 4
Percentage of skin graft survival at week 1 and week 4
Number of patients with recurrence of HS at 3 and 6 months
Number of patients with recurrence of disease at 3 and 6 months
Number of patients with improved Dermatology Life Quality Index (DLQI)
Dermatology Life Quality Index (DLQI) will be used to measure the improvement in quality of life. Comparison will be made between DLQI during pre operative period and 6 months post operative
The difference in cost between both treatments
Data on the total cost of treatment between both treatment groups will be compared. The total cost will combine the cost of procedures, cost of devices, cost of inpatient stay and cost of clinic follow ups.
Full Information
NCT ID
NCT04325607
First Posted
January 16, 2020
Last Updated
March 26, 2020
Sponsor
Royal Free Hospital NHS Foundation Trust
Collaborators
KCI Europe Holding B.V.
1. Study Identification
Unique Protocol Identification Number
NCT04325607
Brief Title
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
Acronym
HIDRA
Official Title
A Randomized Controlled Trial to Evaluate the Efficacy of Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Unknown status
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
August 2022 (Anticipated)
Study Completion Date
November 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Royal Free Hospital NHS Foundation Trust
Collaborators
KCI Europe Holding B.V.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The current surgical management for severe Hidradenitis suppurativa (HS) involves wide excision of affected skin, resulting in a large soft tissue defect. The soft tissue defect will then be managed with Negative Pressure Wound Therapy (NPWT) to promote healthy granulation tissue formation for wound coverage with Split skin graft (SSG). This long interval between excision and reconstruction could result in long in-patient stay, increased risk of hospital acquired infection and reduced patients' quality of life.
The investigators wish to evaluate the use of Negative Pressure Wound Therapy with instillation (NPWTi), which has potential to allow early wound coverage with SSG, as an alternative to the current standard of care. The investigators hypothesise that NPWTi reduces bacterial load on the wound and allows early wound coverage hence improves patient satisfaction and reduces cost and length of hospital stay.
Detailed Description
HS is a recurring chronic skin disease of the hair follicle that usually presents with painful and inflamed lesions in the sweat gland-bearing areas of the body. The lesions often progress to become chronic with pus discharge and scar formation resulting in significant disability.
Current surgical management for severe HS involves surgical removal of all involved hair bearing skin resulting in large areas of soft tissue loss which requires reconstruction. The wound is reconstructed by performing skin grafting, known as SSG, whereby a healthy layer of skin is transferred to the area of tissue loss. SSG enables rapid wound healing and has low risk of recurrence of HS. Skin grafting is often done a few weeks after excision of HS (delayed setting) to ensure higher success rate due to the infected nature of HS. During the interval between surgical removal of areas with HS and skin grafting, the wound is managed with a suction dressing known as the Negative Pressure Wound Therapy (NPWT) to promote formation of healthy wound bed. NPWT is a form of vacuum dressing which applies continuous suction pressure on the wound to remove fluids and bacteria from the wound bed.
The NPWT is highly successful in managing such wounds, however a novel and innovative improvement to this technology with an irrigation system, the Negative Pressure Wound Therapy with instillation (NPWTi), holds promise to enhance production of healthy wound bed and further reducing bacteria and infectious materials from the wound, enabling earlier wound coverage with SSG. The NPWTi involves irrigating and soaking the wound with fluid, followed by removal of the fluid via application of suction pressure at timed, regular intervals. The goal of the instillation therapy is to enable early application of SSG as wound irrigation has long been appreciated as beneficial for cleaning contaminated wounds.
The investigators wish to evaluate the NPWTi as an alternative to NPWT for current surgical management strategy of severe HS. The investigators wish to determine if NPWTi allows early wound coverage with SSG which improves patient satisfaction and reduces length of hospital stay. This research will further our knowledge about the human wound healing process and it may help improve treatment for future patients. The investigators plan to study up to 44 patients in total.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hidradenitis Suppurativa
Keywords
Hidradenitis Suppurativa, Negative pressure wound therapy with instillation, Negative pressure wound therapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
44 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Negative Pressure Wound Therapy with instillation
Arm Type
Experimental
Arm Description
Patients in the treatment group will be initiated on VeraFlo instillation (NPWTi) therapy upon excision of HS
Arm Title
Negative Pressure Wound Therapy
Arm Type
Active Comparator
Arm Description
Patient in the control group will be initiated on VAC therapy (NPWT) upon excision of HS
Intervention Type
Procedure
Intervention Name(s)
Excision of HS followed by NPWTi
Other Intervention Name(s)
VAC VERAFLO™ Therapy
Intervention Description
The NPWTi that will be used in this study will be the V.A.C. VERAFLO™ Therapy (KCI)
Intervention Type
Procedure
Intervention Name(s)
Excision of HS followed by NPWT
Other Intervention Name(s)
VAC Therapy
Intervention Description
The NPWT that will be used in this study will be the V.A.C.® Therapy(KCI)
Primary Outcome Measure Information:
Title
The mean days to wound coverage with split skin graft (SSG) after excision of HS
Description
Mean days to wound coverage with split skin graft (SSG) after excision of HS in each treatment arm
Time Frame
2 weeks
Title
The difference in bacterial count on the wound after NPWTi against NPWT
Description
Reduction in the number of colony-forming unit (CFU) at each dressing change analysed using tissue culture of wound bed biopsies
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Proportion of wounds covered with SSG at 1 week post excision
Description
The proportion of wounds (in percentage) covered with split skin graft at 1 week post excision.
Time Frame
1 week
Title
Percentage of graft take at week 1 and week 4
Description
Percentage of skin graft survival at week 1 and week 4
Time Frame
4 weeks
Title
Number of patients with recurrence of HS at 3 and 6 months
Description
Number of patients with recurrence of disease at 3 and 6 months
Time Frame
6 months
Title
Number of patients with improved Dermatology Life Quality Index (DLQI)
Description
Dermatology Life Quality Index (DLQI) will be used to measure the improvement in quality of life. Comparison will be made between DLQI during pre operative period and 6 months post operative
Time Frame
6 months
Title
The difference in cost between both treatments
Description
Data on the total cost of treatment between both treatment groups will be compared. The total cost will combine the cost of procedures, cost of devices, cost of inpatient stay and cost of clinic follow ups.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female
Age 18-90 at the time of consent
Clinical diagnosis of axillary hidradenitis suppurativa
Unilateral axillary hidradenitis suppurativa (if bilateral disease, only one side will be included into study).
Hidradenitis suppurativa with multiple sinuses which are not able to close directly
Not on antibiotics for 6 weeks
Patient understands and is willing to participate
Exclusion Criteria:
Hidradenitis suppurativa with isolated sinus for direct closure
Patient with ongoing chemotherapy or radiotherapy
Patient with active cancer
Uncontrolled Diabetes Mellitus, as measured by an HbA1c > 10%.
BMI over 35
Active smoker
Presence of one or more medical conditions, including renal, hepatic, hematologic, active auto-immune or immune diseases that, would make the subject an inappropriate candidate for this wound healing study
Patient not fit for surgery (ASA classification > 4)
Patients not able to consent for procedure in English
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Muholan Kanapathy, PhD
Phone
020 7794 0500
Email
m.kanapathy@ucl.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ash Mosahebi
Organizational Affiliation
Royal Free NHS Foundation Trust London
Official's Role
Study Director
Facility Information:
Facility Name
Royal Free NHS Foundation Trust Hospital London
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ibby Younis
Phone
020 7794 0500
Ext
35556
Email
ibbyyounis@nhs.net
First Name & Middle Initial & Last Name & Degree
Ibby Younis, Phd
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Negative Pressure Wound Therapy With Instillation for Treatment of Hidradenitis Suppurativa
We'll reach out to this number within 24 hrs